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Background: Human Adenoviral vectors (HAdV) are immunogenic vectors which have been tested in many
vaccination and gene therapy settings. Dendritic cells (DC) transduced by genetically engineered HAdV-5 (HAdV-5/DC),
are investigational cancer vaccines being tested clinically. We have previously examined immune responses
to HAdV-5 -encoded melanoma tumor antigens. Here, we determined whether the HAdV-5/DC also present
immunogenic HAdV-5 vector-derived antigens, and characterized the cellular immune response to the viral as
well as encoded melanoma tumor antigens.
Methods: Both CD4+ and CD8+ HAdV-5-specific T cell responses were examined in vitro, with cells from both 8
healthy donors (HD) and 2 melanoma patients. PBMC were stimulated weekly with HAdV-5/DC and responses
were examined after each stimulation. We also tested HAdV-5 neutralizing antibody levels and natural killer (NK)
cell and regulatory T cell (Treg) activation and expansion in vitro.
Results: HAdV-5/DC rapidly induced a high frequency of type 1 cytokine producing HAdV-5-specific CD8+ and
CD4+ T cells. IFNγ and TNFα-producing T cells predominate. Those with pre-existing cellular memory to HAdV-5
had more robust responses to the HAdV-5 as well as tumor-associated antigens. NK cells are activated while Treg
are only minimally and transiently expanded.
Conclusions: This study demonstrates that HAdV-5/DC promote strong type I cellular immunity to viral vector-derived
antigens as well as to the encoded tumor antigens. The cytokine and chemokine milieu produced by HAdV-5/DC and
the activated HAdV-5-specific T cells may enhance responses to encoded tumor antigens as well. These properties
make HAdV-5/DC a cancer vaccine capable of activating type 1 virus and tumor antigen-specific immunity in a
cooperative way.
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Recombinant Human adenovirus serotype 5 (HAdV-5)
is the most commonly used gene transfer vehicle with a
long safety record [1]. The HAdV-5 36 kb genome
(double stranded DNA) is well characterized, and used
in many experimental and clinical settings [2]. Its systemic
use in vaccination and gene therapy has been limited by
pre-existing immunity and the presence of neutralizing* Correspondence: butterfieldl@upmc.edu
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reproduction in any medium, provided the orantibodies in environmentally exposed individuals.
Neutralizing antibodies, directed mainly against capsid
hexon loops, are serotype specific. Approximately 45%
of adults in the United States possess neutralizing
antibodies to HAdV-5. A variety of other Adenoviral
subtypes and deletion mutants have been investigated
(Ad28, Ad35 and “gutless” Adenovirus), in an attempt to
circumvent pre-existing immunity in exposed individuals.
We have utilized E1/E3-deleted, replication deficient
tumor antigen-encoding HAdV-5 in vitro and in vivo, to
promote tumor antigen-specific immunity (reviewed in
[3]. As previously shown, dendritic cells (DC) transduced
with an HAdV-5 (HAdV-5/DC) encoding full lengthLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CD8+ and CD4+ T cells in vitro [4,5] and in vivo [6].
Similarly, DC transduced with an HAdV-5 encoding
alpha fetoprotein (AFP, HAdV-5hAFP) activate CD8+
and CD4+ T cells to AFP in vitro, and are more efficient
at T cell stimulation than AFP protein-fed DC [7-9].
Immunogenicity of HAdV-5/DC can be attributed to
the fact that HAdV-5 transduction promotes a more
mature DC surface phenotype, associated with a unique
cytokine and chemokine secretion profile [10,11]. Add-
itionally, transduction with HAdV-5 modulates compo-
nents of MHC class I antigen processing machinery in
DC [11]. Recently we showed that HAdV-5/DC can
also promote NK cell chemotaxis in vitro and in vivo
via IL-8/CXCL8 and IP-10/CXCL10 secretion and
induce activation of both major subsets of NK cells,
which requires cell-cell contact via cell surface TNF
and IL-15 [12,13].
We have examined the cross-talk between HAdV-5
and DC, as well as downstream effects on transgene-
specific T cell subsets and other lymphocytes. In addition
to introducing a transgene, HAdV-5 engineering of DC
also leads to expression of the remaining HAdV-5
genes encoded within the vector (derived from 28
genes and overlapping open reading frames) in the DC,
and processing and presentation of viral coat proteins,
such as the HAdV-5 hexon and fiber, released during
HAdV-5 uptake in endosomes. The immunologic impact
of the presentation of these viral proteins by transduced
DC to T cells is yet unknown. Our previous preclinical
murine models indicated that pre-immunization with
HAdV-5 did not impact the antitumor immunity from an
AdVMART-1-transduced DC vaccine [14], but detailed
viral immunity assessments were not performed because
mice are not permissive for HAdV infections.
Most previous studies examining humoral and cellular
immunity to HAdV-5 have focused on directly injected
vectors, and vectors involving HIV antigens encoded by
HAdV-5. Humoral responses to HAdV-5 were shown
to be critical to the efficacy of an HIV vaccine [15]. It
has been shown that HAdV-5 neutralizing antibody
levels were unrelated to T cell responses to hexon or
E2A viral proteins, and that the levels of HAdV-5-
specific CD4+ T cell responses varied with the specific
deletions in the HAdV-5 backbone [16]. Multiplex cyto-
kine profiling showed that a broad Th1/Th2/regulatory
profile resulted from MRKAd5 HIV gag immunization of
healthy volunteers [17].
Other previous clinical studies utilizing recombinant
HAdV-5 vectors encoding additional foreign viral anti-
gens (HIV, EBV, CMV) have examined some aspects
of immune response to the HAdV-5 viral antigens
[14,15,18-23]. Other reports in the literature utilize
replication-competent HAdV-5 which still encode theE1a/E1b transactivators (including oncolytic viruses),
leading to a high level of viral gene transcription and
translation, and often lytic growth in infected human
cells. However, the responses to recombinant HAdV-5
which encode normal, non-mutated self-antigens, like
melanoma lineage tumor antigens, may have a unique
profile due to the colocalized presentation of both classes
of antigens (self and viral). Such self-antigen encoding
HAdV-5 have been tested in transduced DC clinical
trials [6,22,23], but the immunity to the HAdV-5 aspects
of these vaccines has not been examined to date.
We have recently developed a new melanoma vaccine
clinical trial testing immunization with three full length
melanoma tumor antigens (HAdV-5 TMM2, encoding
Tyrosinase, MART-1 and MAGE-A6), instead of a single
antigen [24], as in our previous trial [6]. While we have
previously characterized the T cell responses to the
encoded tumor antigens, we have not examined whether
HAdV-5-specific cellular immune responses are also
activated. Based on previous studies showing that the
HAdV-5 capsid protein hexon encodes CD8 and CD4
T-cell epitopes [25,26], we hypothesized that HAdV-5-
specific memory T cells may be detected in the periphery
of environmentally exposed individuals, and that these
responses might be quickly reactivated with HAdV-5/DC
stimulation. We also hypothesized that these responses
would be predominantly type 1, which might serve to
skew the cellular environment in which the virally
encoded tumor antigens are presented. Here, we have
carefully examined the in vitro CD8+ and CD4+ T cell
response to HAdV-5-specific antigens on DC transduced
with a replication-deficient HAdV-5 (HAdV-5 TMM2).
We find that a high frequency of type 1 CD8+ and CD4+
T cells are activated to the viral antigens and the overall
cytokine milieu is type 1. We also find that NK cells in
culture are activated, and regulatory T cells (Treg) remain
at a low frequency in vitro, while activated CD4+ T cells
expand. Importantly, HD and melanoma patients with
pre-existing cellular HAdV-5-specific memory T cells
showed potent HAdV-5 and melanoma antigen responses
in vitro which were unrelated to humoral memory.
Results and discussion
HAdV-5/DC rapidly induce high frequencies of
HAdV-5-specific CD4+ T cells
To define the CD4+ T cell response to HAdV-5 in HD,
we stimulated PBMC with HAdV-5 TMM2-transduced
DC (HAdV-5 TMM2/DC) in vitro, for a total of three
weekly stimulations. This was chosen to mimic the three
total vaccinations used in our current and previous clinical
trials [6,27,28]. We hypothesized that we would expand
high frequencies of type 1 T cells, based in part on the
HAdV-5 virus-specific T cell adoptive transfer studies
[20] which have demonstrated that HAdV-5-specific
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capacity, secrete IFNγ and show cytotoxicity towards
HAdV-5-infected targets [21]. T cells were tested weekly,
after each stimulation. We utilized two standardized,
functional assays to measure responses, using the cytokine
ELISPOT from purified T cell subsets, and flow cytometry
with surface and intracellular cytokine staining. Mean
HAdV-5-specific CD4+ T cell frequencies for 7 HD are
shown in Figure 1A, 1B, and 1C.
While several promiscuous MHC class II epitopes have
been described (Hex571-600, Hex856-885, Hex901-930) [29], we
primarily detected responses to the HAdV-5 hexon901-930
(Hex901-930) epitope. As shown in Figure 1A, after only a
single HAdV-5 TMM2/DC stimulation, a high frequency
of Hex901-930-specific CD4
+ T cells were expanded, pro-
ducing primarily IFNγ, as well as TNFα and IL-2. Low
frequencies of IL-10 producing cells were also detected
from HD. TNFα or IL-10 responses to the Hex571 and
Hex856 epitopes were not detected and there were few
examples of IFNγ or IL-2-producing T cells detectedC
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Figure 1 HAdV-5-specific CD4+ T cell responses. PBMC were cultured w
1 week, followed by 2 restimulations with HAdV-5 TMM2/DC (weeks 1 and
tested by direct ELISPOT for recognition of hexon901-930 peptide (A) or full
producing cells from seven donors is shown. These cells were also tested f
be low, averaging at 0.05% at week 3 (data not shown). (C). Data from 7 in
responding to HAdV-5 LacZ or HAdV-5 TMM2 (HAdV-5 plus melanoma ant
polyfunctional, simultaneous IFNγ + IL-2-producing cells (D). Error bars repr
single tailed student’s t-test (p < 0.05).specific to Hex856 (not shown). Since the HAdV-5 hexon
capsid protein is very immunogenic and has been found
to account for the majority of anti-HAdV-5 T cell
reactivity in other studies [21], we hypothesized that
other HAdV-5-derived epitopes might play an important
role in HAdV-5/DC induced T cell responses. We used
an E1/E3-deleted HAdV-5 encoding β-galactosidase
(HAdV-5 LacZ), which has the same HAdV-5 backbone
as HAdV-5 TMM2 and which also encodes the same
28 overlapping HAdV-5 gene products as HAdV-5
TMM2, to measure the total HAdV-5-specific T cell
responses. While the hexon-specific responses peaked
at one week (all measured cytokines), the total HAdV-5
response, largely consisting of IFNγ and TNFα-producing
T cells, continued to increase through three weekly
stimulations (Figure 1B). The difference in expansion
kinetics between hexon-specific and total HAdV-5-
specific CD4+ T cells may be due to the minimal levels
of viral gene transcription and the presence of intact
hexon protein in the coat of AdVTMM2. Comparing0
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ith autologous DC transduced with HAdV-5 TMM2 (baseline) for
2) and harvest (week 3). (A and B): CD4+ T cells were purified and
length HAdV-5 (HAdV-5 LacZ, B). The mean frequency of cytokine
or IFNγ and IL-2 production by flow cytometry, which was found to
dependent HD is shown. Identically cultured melanoma patient cells
igens) is shown (n = 2, averaged), for total IFNγ-producing cells and
esent standard error of the mean. *Significant response vs. baseline by
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(HAdV-5 LacZ) with the response to both HAdV-5 and
the three melanoma-associated antigens (MAA, HAdV-5
TMM2), a minimal IL-2 response was detected at week
2 and a stronger IFNγ response was observed after
three stimulations, with specificity for both viral and
melanoma antigens (Figure 1C). The frequency of CD4+ T
cells which were polyfunctional (producing IFNγ and IL-2
simultaneously by flow cytometry) was low, averaging
0.05% of CD4+ T cells at the peak at week 3 (not shown).
Cancer patients can be immune suppressed, due to
multiple immune modulatory effects of both tumor cells
and many standard of care cancer treatments. Therefore,
it was important to include cancer patient cells in the
analysis. We used IFNγ-producing HAdV-5-specific
CD4+ T cells obtained from two different melanoma
patients also expanded to high frequencies in vitro.
Despite these virus-specific T cell frequencies, the T cells
specific to the three encoded melanoma antigens were still
detectable, at over 1% frequency, at week 3 (Figure 1D).
Interestingly, the frequency of polyfunctional CD4+ T
cells was higher in both of the patient cell cultures (0.3
and 0.8% at week 3, not shown) than in HD cultures,
indicating that the tumor and therapeutic treatments
received did not inhibit HAdV-5 or tumor antigen
responses. Conceivably, immunotherapies received by
these patients may have supported previous expansion
of the melanoma antigen-specific T cells, allowing for
memory responses.
HAdV-5-specific CD8+ T cell responses are rapidly induced
by HAdV-5/DC
To define the CD8+ T cells response to HAdV-5 in HD,
we utilized the same culture and assay strategy. We tested
the HLA-A2-restricted hexon711-721 peptide previously
identified as the immunodominant hexon epitope, but
did not reliably detect responses from any of our HLA-A2+
donors (data not shown). We did detect high frequency
type 1 responses to the total HAdV-5 proteins (HAdV-5
LacZ) as shown in Figure 2. Cells producing TNFα and
IFNγ predominated and showed greater frequencies
with every subsequent stimulation, with IL-2 producing
cells also detected (Figure 2A). Comparing the HAdV-5
and HAdV-5 +MAA responses, CD8+ T cells producing
IFNγ and IL-2 (at a lower frequency) could be detected
to both after 3 stimulations (Figure 2B). Comparing
CD4+ and CD8+ T cell responses, there were more
IFNγ-producing CD4+ T cells and more IL-2-producing
CD8+ T cells expanded from the HD tested (Figures 1C
and 2B). The frequency of polyfunctional HAdV-5-specific
CD8+ T cells was also low, averaging 0.04% of CD8+ T
cells at the peak at week two (not shown).
To confirm that the patterns observed in HD were
representative of the responses in melanoma patients,we repeated the experiments with PBMC from the same
HAdV-5anced stage melanoma patients (Figure 2C).
While HAdV-5-specific cells were clearly expanded, the
relative frequency of melanoma antigen to HAdV-5 viral
antigen responses was much greater than in CD4+ T
cells (Figure 1C). The frequencies of polyfunctional
CD8+ T cells in the two patients were similar to that of
the HD (0.05%, peak at week 1, not shown).
Impact of HAdV-5-specific cellular memory responses
Because most individuals have been previously exposed
to HAdV-5 in the environment, we expected that donors
and patients would have variable but detectable levels of
pre-existing cellular and humoral HAdV-5 immunity.
Additional file 1: Figure S1 shows the range of anti-
HAdV-5 neutralizing antibodies detected in our pool of
donors and patients. These data show that the majority
of donors and patients have been exposed to HAdV-5
and have detectable titers of neutralizing antibodies, as
expected. The two melanoma patient’s sera did not differ
appreciably from the HD sera tested. Importantly, the
baseline titer of anti-HAdV-5 neutralizing antibodies
did not correlate with the induced cellular response to
HAdV-5 in vitro. This is similar to the observation of
Koup et al. [16] in their study of intramuscular HAdV-
5-HIV gag immunization.
We next determined the impact of baseline cellular
immunity to HAdV-5 on the resultant expansion of T cells
from HAdV-5/DC stimulation. By intracellular cytokine
staining, all tested donors had at least 0.02% positive IFNγ
or IL-2 producing CD4+ and/or CD8+ T cells, and the
assay sensitivity is reported to be 0.01% or less [30].
To investigate the impact of baseline HAdV-5-specific
cellular memory on the level of induced T cell responses
to HAdV-5 antigens as well as MAA, we used a cut off
of 0.03% baseline CD8+ or CD4+ positivity (IFNγ or IL-2)
to compare the induced T cell responses between those
with ≤0.02% positive HAdV-5-specific T cells (the lowest
detected), to those with ≥ 0.03% positive HAdV-5-specific
T cells. As shown in Figure 3, those with cellular memory
responses (red symbols) generally induced higher frequency
CD8+ IFNγ and IL-2 responses to HAdV-5 antigens
and MAA after the three stimulations (Figure 3A-B).
This baseline memory group also showed higher CD4+
IFNγ responses at 2–3 weeks to the HAdV-5 and HAdV-5
TMM2 (HAdV-5 +MAA) groups. The melanoma anti-
gen-specific responses were stronger (with both IFNγ and
IL-2) from those with baseline HAdV-5 cellular memory
(Figure 3A-D). Importantly, the IL-2 producing T cells
recognizing autologous DC pulsed with lysate from the
melanoma cell line Mel526 (expressing Tyrosinase, MART-
1, MAGE-A3/6 antigens, not shown) were also most
frequently recognized by those with HAdV-5 cellular
memory (Figure 3E). These data suggest that the higher
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Figure 2 HAdV-5-specific CD8+ T cell responses. CD8+ T cells were cultured as described in Figure 1, and were tested for responses to HAdV-5
and melanoma antigens. (A) The mean frequency of CD8+ T cells from 7 donors responding to HAdV-5 by ELISPOT is shown. (B) These cells were also
tested for IFNγ and IL-2 production by flow cytometry. Data from 7 independent HD is shown. Identically cultured melanoma patient cells responding
to HAdV-5 LacZ or HAdV-5 TMM2 (HAdV-5 plus melanoma antigens) is shown (n = 2, averaged), for total IFNγ-producing cells and polyfunctional,
simultaneous IFNγ + IL-2-producing cells (C). Responses were highest at week 3 for 5 of 7 donors and 1 of 2 patients. *Significant response vs. baseline
by single tailed student’s t-test (p < 0.05).
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cytokines provides a supportive milieu for the MAA-
specific T cells also being stimulated by the HAdV-5
TMM2/DC.
Our observation of robust expansion of type 1 cytokine
producing HAdV-5-specific T cells is in sharp contrast to
the lack of expansion of HAdV-5-specific T cells in vivo
after HAdV-5-HIV gag vaccination [16]. This may relate
in part to the difference in HAdV-5 backbone. The HIV
gag-encoding vector in that study was not only E1 and
E3 deleted, but also E4 deleted.
HAdV-5 TMM2/DC promote NK cell activation in vitro
Our previous data showed that HAdV-5 LacZ/DC can
activate NK cells [12]. Therefore, we examined the acti-
vation status of NK cell subsets in the HAdV-5 TMM2/
DC cultures. The NK cells were separately analyzed as
two major and three minor subsets (Additional file 2:
Figure S2a), as described previously [31]. We observedthat the frequency of total activated CD69+ NK cells
(Additional file 2: Figure S2b) and activated IFNγ-
producing NK cells (Additional file 2: Figure S2c) in-
creased with HAdV-5 TMM2/DC stimulation. These
data confirm that HAdV-5 TMM2/DC promote NK cell
activation, and that changing the encoded transgene from
xenoantigens β-galactosidase or luciferase to melanoma
tumor antigens tyrosinase, MART-1 and MAGE-A6 does
not change the ability to activate NK cells.
HAdV-5 TMM2/DC do not induce regulatory
T cell responses
There have been reports of certain types of DC activating
suppressive Treg responses [32]. Such expansion of Treg
would be an unwanted side effect of HAdV-5/DC
stimulation in a cancer immunotherapy setting. There-
fore, we determined the overall levels of both CD4+ T
cell activation (regardless of antigen specificity), as well
as levels of Treg in the HAdV-5/DC cultures by flow
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Figure 3 Impact of baseline memory on induced responses. The frequency of CD8+ (A and B) and CD4+ (C and D) T cells producing
IFNγ (A and C) or IL-2 (B and D) to HAdV-5 (HAdV-5 LacZ) or HAdV-5 +melanoma antigens (HAdV-5 TMM2) are shown (“All”). Those HD with≥ 0.03%+
baseline IFNγ and/or IL-2 responses were also analyzed separately, as having cellular memory responses (“mem”, n = 5) vs. those with < 0.03%+ cells, or
no baseline cellular memory (“no mem”, n = 2). The frequency of CD8+ or CD4+ T cells producing IL-2 to DC loaded with Mel526 lysate are shown (E).
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http://www.immunotherapyofcancer.org/content/1/1/19cytometry. As shown in Figure 4A and B, the frequency of
activated (CD25+) CD4+ T cells were sharply increased
after a single stimulation with HAdV-5/DC to 15-40%
of the total CD4+ T cells, later decreasing to 8-27%. In
contrast, the frequency of CD25hi FoxP3+ CD4+ Treg
detected was extremely low (<4%), and decreased to <1%
after the third HAdV-5/DC stimulation (Figure 4C). This
could be attributed to the fact that HAdV-5/DC have a
unique level of maturation where they secrete low
amounts of immunoregulatory cytokines (IL-10 and IL-13), and more immunostimulatory cytokines (TNFα,
IL-15) [11].
Cytokine and chemokine milieu
As shown in Figures 1 and 2, we detected high frequencies
of HAdV-5-specific T cells producing primarily IFNγ
and TNFα. We also measured CD69 on all T cells, to
determine the activation status on a population basis.
At baseline, 2% of CD4+ T cells and 4% of CD8+ T cells
were CD69+, and PMA/ionomycin activation resulted in
05
10
15
20
Baseline Week 1 Week 2 Week 3
%
 C
D
4+
/C
D
25
 h
ig
h
 / 
F
o
xp
3>
80
%
 c
el
ls
 Treg  change during AdVTMM2 IVS 
Exp. 10-1
Exp.11-1
Exp. 12-2
Exp.17
Exp.18
0
10
20
30
40
50
Baseline Week 1 Week 2 Week 3
%
 C
D
4+
/C
D
25
+ 
ce
lls
 
Total activated CD4+ T cells   
Exp. 10-1
Exp.11-1
Exp. 12-2
Exp.17
Exp.18
B C
A
010 110 210 310
CD25 APC
Week 3
[C]
E: 0.21%
G: 1.92%
I3:0.00% I4:0.00%
I1 I2:8.32%
010 110 210 310
CD25 APC
Week 2
[C]
E: 0.80%
G: 4.14%
I3:0.00% I4:0.00%
I1 I2:13.94%
010 110 210 310
CD25 APC
Week 1
[C]
E: 1.59%
G: 11.70%
I3:0.00% I4:0.00%
I1 I2:39.92%
010 110 210 310
10 0
10 1
10 2
10 3
CD25 APC
C
D
4
FI
TC
Baseline
[C]
E: 0.01%
G: 0.68%
I3:0.00% I4:0.00%
I1 I2:10.42%
Activated T cells/Treg
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(up to 89%) of IFNγ and/or IL-2-producing cells were
CD69+, as expected. Of the 11-24% which expressed
CD69 following HAdV-5 LacZ/DC exposure, less than
1% generally produced IFNγ or IL-2 (Figures 1 and 2).
Therefore, we hypothesized that additional cytokines
were likely being produced by these CD69+ activated T
cells. To more broadly characterize the cytokine milieu
(created by both HAdV-5/DC and lymphocytes), we
tested many soluble factors present in the HAdV-5/DC
cultures at each weekly stimulation by multiplex Luminex
assay. As shown in Figure 5, many cytokines and che-
mokines were detected. In addition to IFNγ and TNFα,
MCP-1/CCL2, RANTES/CCL5, IL-7 and GM-CSF were
highly produced. IL-7 has anti-apoptotic properties and
may also serve to support T cell growth and GM-CSF may
aid DC viability [33,34]. Based on our recent findings
on NK cell crosstalk, we examined both CXCL8/IL-8
and CXCL10/IP-10, which we demonstrated are secreted
by HAdV-5/DC and responsible for NK cell chemotaxis
[13]. Both were detected at high levels, which would
support NK cell chemotaxis at each weekly stimulation
(as well as possibly chemotaxis of neutrophils and type
1 T cells, respectively). IL-15, which we showed is crucial
for HAdV-5/DC-mediated NK cell activation (when trans-presented on the DC surface), and which has also been
shown to support memory T cell homeostasis was also
detected [35].
There have been reports of type 1 interferons (IFN)
produced by a variety of human cells upon HAdV-5
exposure, which might be expected as part of an antiviral
response [36]. HAdV-5 induction of IFNα has been shown
to have a variety of positive and negative effects in the
setting of recombinant HAdV-5 vaccines [37]. IFNα is
also known to help mature DC, promote CD8+ T cell
growth, support memory responses, and support NK
cells [38]. In these in vitro cultures, we detected low
levels of IFNα, generally under 100 pg/mL. These levels
(which are well below physiologically achieved levels in
high dose IFNα-treated patients) may be too low to
promote DC maturation [10].
We did not detect VEGF or IL-2 by Luminex. As shown
in Figures 1 and 2, IL-2-producing T cells were detected
by intracellular cytokine staining, but levels of soluble
IL-2, a potent T cell growth factor, were either below
detection or more likely taken up by other cells in culture.
In contrast, soluble IFNγ and TNFα, also produced by
antigen-specific T cells, were within detection limits in the
cultures. VEGF is a potent inducer of angiogenesis and
skews immunity to support tumor growth, hence the lack
10
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Figure 5 Analytes in weekly HAdV-5 TMM2/DC cultures by Luminex. Cell-free supernatents were collected after each 7 day culture period
and frozen until simultaneous testing by multiplex Luminex 30-plex assay. The average levels for each analyte detected are shown at each time
point, pooling 4–7 HD and 2 melanoma patients’ culture data.
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with lymphocytes. Lastly, we detected low levels of IL-17,
which may be produced by pro- or anti-tumor T cells [39].
The role of Th17 cells in our system is not yet known,
but these preclinical data suggest that these cells should
be tested in our clinical trial patients.
When comparing HD to melanoma patient (results
not shown), the patients had lower levels of IL-10, IL-6,
IL-15, MCP-1, IL-Ira, IP-10, MIG and IL-8 and higher
levels of MIP-1α and GM-CSF, although higher num-
bers of HD and patients are needed to determine the
significance of these observations. We did not detect
a correlation between neutralizing antibody levels and
cytokines produced in HD or patient cell cultures.
A study of HD vaccinated intramuscularly with
MRKAd5-HIV-1 gag tested the cytokine profiles of
PBMC at 30 weeks post injection [17]. The array of
analytes tested was similar to ours. IL-8, MCP-1 and
IP-10 were found in similar concentrations and were
also the highest produced analytes in their study, sup-
porting the potential in vivo relevance of our findings.
However, there were also several differences between
their findings and ours, including higher levels of
IFNγ, GM-CSF, lower levels of IL-6 and IL-10 and no
VEGF detected in our study. It will be important to
confirm the quality and frequency of these cellular
and secreted molecule responses presented with the
in vivo responses in patients vaccinated with HAdV-5
TMM2/DC.Conclusions
We find that DC engineered with a replication-deficient
Ad5 vector encoding three melanoma antigens activate
high frequencies of HAdV-5-specific CD4+ and CD8+
T cells. These T cells produce both IFNγ and TNFα
effector cytokines, which create a type 1 cytokine milieu,
and which have recently been shown to be important
to promote senescence in tumors [40]. These cellular
responses were independent of the level of anti-HAdV-5
humoral immunity. Interestingly, those with pre-existing
cellular memory to HAdV-5 had superior responses not
only to the HAdV-5 but also to the melanoma antigens.
This suggests that the type 1 virus-specific T cell response
may support a response to the vector-encoded melanoma
antigens. We will investigate this in our ongoing HAdV-5
TMM2/DC vaccine clinical trial, in vivo. Additionally, we
reaffirmed the ability of HAdV-5/DC to activate NK cells
and not Treg, which can further aid in the creation of
the type 1-skewing milieu, as well as provide an innate
cytotoxic response against tumors.
Methods
Cell culture and cell lines
Mel526 is a human melanoma cell line which expresses
MART-1/Melan-A, tyrosinase and MAGE-A3/6. The cell
lines (Mel526, HEK293, A549) were cultured in Advanced
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS), 1% penicillin streptomycin and 1% L-glu-
tamine (all reagents from Invitrogen), in a humidified
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was prepared by repeated freeze/thaw of a cell pellet.
Peptides
Peptides were synthesized at the University of Pittsburgh
Peptide Synthesis Facility using standard f-moc technology.
Stock solutions were prepared in DMSO (10 mg/mL)
and were kept at −80°C until use. HAdV-5 hexon711–721
TFYLNHTFKK and the HAdV-5 promiscuous hexon
peptides: 571–600 NLLLLPGSYTYEWNFRKDVNMVLQSS
LGND, 856–885 VDSITQKKFLCDRTLWRIPFSSNFMSM
GAL and 901–930 LDMTFEVDPMDEPTLLYVLFEVFDV
VRVHR.
Virus amplification, purification and titer
Virally infected HEK 293 cells (ATCC, #CRL-1573) were
freeze/thawed and the cleared supernatant was layered
onto a CsCl step gradient (1.2 g/mL/1.4 g/mL) and centri-
fuged at 35,000 rpm 1.5 h. The virus band was dialyzed
(Pierce Slide-a-lyzer 10 K, Tris/MgCl2/glycerol), and
concentrated (Millipore) in formulation buffer (2.5%
glycerol (w/v), 25 mM NaCl and 20 mM Tris–HCl,
pH 8.0; Clontech), aliquoted and titered (Adeno-X Rapid
Titer Kit, Clontech). HAdV-5 LacZ was obtained from
the University of Pittsburgh Vector Core. HAdV-5 TMM2
encodes a CMV-Tyrosinase-IRES-MART-1-SV40pA cas-
sette in the E1 region, and an RSV-MAGE-A6-SV40pA
cassette in the E3 region [24].
RT-PCR
Total RNA was isolated (Qiagen Kit; Qiagen) and quan-
tified by UV spectrophotometry. RT-PCR was performed
using Random Primers, and SuperscriptTM III Reverse
Transcriptase, Ampli Taq Gold polymerase. Sequenced-
specific primers were as follows:
Tyrosinase, Forward: 5’-ATT-CCA-TAT-TGG-GAC-
TGGCGG-GAT-3’/Tyrosinase
Reverse: 5’-CAA-TGG-GTG-CAT-TGG-CTT-CTG-
GAT-3’
MART-1, Forward: 5’ – TGC-AGA-TAT-CCA-TCA-
CACTGG-3’
Reverse: 5’ – GGA-GGG-GCA-AAC-AAC-AGA T – 3’
MAGE-A6, Forward: 5’- AGT-AGG-AAG-GTG-GCC-
AAGTTG-GTT-3’
Reverse: 5’- TAT-TGG-GTG-AGC-TTC-TTGGGA-3’
β-Actin, Forward: 5’-GGC-ATC-GTG-ATG-GAC-
TCC-G-3’
Reverse: 5’-GCT-GGA-AGG-TGG-ACA-GCG-A-3’
All primers were prepared by Integrated DNA Tech-
nologies, Inc. PCR reactions for β-Actin, Tyrosinase and
MART-1 were 32 cycles (61.7°C annealing), and for
MAGE-A6, 30 cycles (55°C annealing) were used.Isolation of peripheral blood mononuclear cells (PBMC)
Peripheral blood was obtained from 8 different HLA-
A2+/−/HLA-DR4+/− normal donors with their written
consent, under an IRB-approved protocol (UPCI 04–001,
L. H. Butterfield, PI).
Melanoma patient PBMC were obtained under Protocol
UPCI 96–099 (J. M. Kirkwood, PI) at a time point distant
from any treatment. Patient #1 was diagnosed at stage 1,
and 5 years post diagnosis, an inguinal metastases was
found and she was treated with lymphadenectomy + high
dose Interferon alpha-2b. Patient #2 was diagnosed at
stage 4 and received several previous treatments: Tem-
ozolomide, Interferon, high dose IL-2, BCG plus tumor
vaccine. PBMC were separated from blood using Ficoll-
Hypaque gradient centrifugation (Cellgro; Mediatech,
Inc.) with average viability of 98%. Additional buffy coats
from healthy donors were obtained from the Central
Blood Bank (Pittsburgh, PA).
Generation of dendritic cells (DC) and DC culture
DC were prepared as described [24] with some modifica-
tions. Mononuclear cells (7–8 x 107) were plated in T-75
flasks (Costar) in RPMI 1640/PSF/5–10% human AB
serum for 2 h at 37°C in a humidified CO2 incubator.
The non-adherent cells were removed by gentle rinsing
with PBS, and the loosely-adherent cells were cultured
in medium with 800 U/mL GM-CSF (Sargramostim;
Amgen) and 500 U/mL IL-4 (Schering Plough) for 6–7
d. The DC were harvested by TrypLE select, and had
average 90% viability at harvest, and 85% viability post
HAdV-5 transduction. DC were either transduced at
moi = 500 pfu: DC or loaded with Mel526 lysate at
10 μg/ml for 2 hours at 37°C in serum-free medium,
then washed.
In vitro stimulation
PBMC from HD or patients were stimulated in vitro using
HAdV-5/TMM2 transduced DC in a ratio of 1:10–1:40
(DC:PBMC). 25 ng/ml of IL-7 was added once at setup
of the IVS. 30U/ml IL-2 was added on day 3 of each
IVS to maintain viability. Stimulated PBMC were collected
weekly, washed, and re-stimulated with freshly transduced
DC. A portion of PBMCs were collected from culture
weekly and cryopreserved.
Selection of CD8+ and CD4+ lymphocytes
Before ELISPOT assays, the CD8+ and CD4+ T cells were
sequentially isolated by positive and negative MACS,
respectively, with the use of immunomagnetic beads
following the manufacturer’s instructions (Miltenyi Bio-
tech). Resulting cell populations were 95% CD8+-positive
according to FACS analysis. Viability at culture harvest
for analysis averaged 82%.
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Multi-screen HA plates (Millipore, MAHAS4510) were
coated with 4–10 ug/mL of monoclonal capture Ab
anti-human IFNγ (1-D1K), IL-2 (IL-2-1), IL-10 (9D7)
or TNFα (TNF3/4; all from MabTech), in PBS overnight
at 4°C. After blocking the plates with RPMI/10% AB (1 h,
4°C), CD8+ or CD4+ T cells were plated at 105 cells/well in
duplicate or triplicate wells. Autologous DC (0.5–1 x 105
well) were pulsed with different peptides or transduced
with HAdV-5, rinsed and plated. Control wells contained
T cells (alone or with 0.2 ng/ml PMA+ 0.2 μM ionomy-
cin), T cells with unloaded DC (“no peptide”) or negative
antigen (HIV gag or alpha fetoprotein peptides tested
in a subset of ELISPOT assays) pulsed DC. Cells were
removed and captured cytokine was detected by corre-
sponding biotinylated mAb (MabTech) at 2 μg/mL in
PBS/0.5% BSA. After washing, Avidin Peroxidase Complex
(Vectastain Elite Kit) was added for 60 min. After rinsing,
peroxidase staining was performed with 3-amino-9-ethyl-
carbazole (AEC, Sigma) and stopped by rinsing the
plates under tap water. Spot numbers were automatically
determined with ImmunoSpot imaging system from
Cellular Technology, Ltd. Spots detected to “medium
only” or T cells only were < 10. Spots detected to PMA
+ ionomycin were > 1,000 on average. To calculate the
number of responding T cells, the mean number of
spots detected with DC alone were subtracted from
mean spot numbers induced by antigen-loaded DC.
The range of DC only background subtracted varied by
cytokine examined.Neutralizing antibody assay
Anti-HAdV-5 neutralizing antibodies were detected using
serial dilutions of serum (1:4 to 1:512) cultured with an
indicator cell line, A549 (ATCC), followed by transduction
with an HAdV-5-encoding enhanced Green Fluorescent
Protein (HAdV-5 eGFP), as described [36]. The cells were
tested for the MFI of eGFP by flow cytometry.Luminex assay
Cell-free supernatants were collected from cultures and
frozen at −80°C. They were subsequently thawed and
simultaneously analyzed with the multiplex Luminex
assay (Invitrogen) per manufacturer’s protocol in a BioRad
reader (UPCI Immunologic Monitoring Laboratory). The
following analytes were tested: GM-CSF, IFNγ, IP-10,
MCP-1, TNFα, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, and
IL-10, IL-15,IL-13, IL-17, IL-1Rα, MIP-1β, IL-2r,IL-7
Exotaxin, MCP-1, MIG, MIP-1alpha and RANTES, in a
kit pre-tested for any potential cross-reactivity by the
manufacturer. Controls included the standard curve
and multiplex QC standards (R&D Systems).Additional files
Additional file 1: Figure S1. Anti-HAdV-5 neutralizing antibodies.
Serum from each HD and patient was tested for the level of neutralizing
antibodies to HAdV-5. Assay controls of no HAdV-5 (negative), no serum
(positive) and pooled human AB serum are also shown. GFP expression
in the A549 indicator cells is shown as MFI. The dilution of serum is on the
X axis and the extent of HAdV-5eGFP transduction blockade is plotted.
Additional file 2: Figure S2. NK cells activated and expanded in vitro.
The CD56/CD16 gating strategy (of gated lymphocytes by forward and
size scatter, not shown) is shown in A, and the number in each gate
corresponds to the population analyzed in B and C. The cultured cells
were assessed weekly, and the frequency of activated (CD69+) NK cells
from each gate is shown in B, and the subset of those CD69+ cells
expressing IFNγ is shown in C. Error bars represent standard errors.
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